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Abstract Inhibition of complement factor 5 (C5) reduced
myocardial infarction in animal studies, while no benefit
was found in clinical studies. Due to lack of cross-reac-
tivity of clinically used C5 antibodies, different inhibitors
were used in animal and clinical studies. Coversin (Or-
nithodoros moubata complement inhibitor, OmCI) blocks
C5 cleavage and binds leukotriene B4 in humans and pigs.
We hypothesized that inhibition of C5 before reperfusion
will decrease infarct size and improve ventricular function
in a porcine model of myocardial infarction. In pigs (Sus
scrofa), the left anterior descending coronary artery was
occluded (40 min) and reperfused (240 min). Coversin or
placebo was infused 20 min after occlusion and throughout
reperfusion in 16 blindly randomized pigs. Coversin sig-
nificantly reduced myocardial infarction in the area at risk
by 39% (p = 0.03, triphenyl tetrazolium chloride staining)
and by 19% (p = 0.02) using magnetic resonance imaging.
The methods correlated significantly (R = 0.92, p\ 0.01).
Tissue Doppler echocardiography showed increased sys-
tolic displacement (31%, p\ 0.01) and increased systolic
velocity (29%, p = 0.01) in coversin treated pigs. Inter-
leukin-1b in myocardial microdialysis fluid was signifi-
cantly reduced (31%, p\ 0.05) and tissue E-selectin
expression was significantly reduced (p = 0.01) in the non-
infarcted area at risk by coversin treatment. Coversin
ablated plasma C5 activation throughout the reperfusion
period and decreased myocardial C5b-9 deposition, while
neither plasma nor myocardial LTB4 were significantly
reduced. Coversin substantially reduced the size of
infarction, improved ventricular function, and attenuated
interleukin-1b and E-selectin in this porcine model by
inhibiting C5. We conclude that inhibition of C5 in
myocardial infarction should be reconsidered.
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Introduction
The introduction of early reperfusion therapy of acute
myocardial infarction (MI) in the clinical setting has
decreased morbidity and mortality and improved post-MI
cardiac function. However, a considerable part of the
ischemic myocardium is still lost upon reperfusion.
Ischemia and reperfusion cause liberation of damage
associated molecular patterns (DAMP) from ischemic or
injured cells, activating innate immune responses, a pre-
requisite for the healing process, currently reviewed in
[19]. However, overactivation causes detrimental effects
by injuring the myocardium, an effect termed ischemia/
reperfusion injury (IRI) [22], leading to aggravated infarct
size and pump failure.
Complement is an upstream sensor and effector system
of innate immunity, a key system for immune surveillance
and homeostasis, but also implicated to play a critical role
in the pathophysiology of myocardial IRI [4, 35]. Com-
plement as a danger sensing alarm system relies on soluble
pattern recognition receptors of three different activation
pathways, the classical, the lectin and the alternative
pathway [35]. They all converge at the central component
C3, which is cleaved into C3a and C3b and subsequently
leads to cleavage of C5, which generates the potent ana-
phylatoxin C5a and the terminal C5b-9 complement com-
plex, both exerting proinflammatory effector functions
[35].
Complement inhibition in myocardial infarction was
first shown to reduce infarction size in rodents already in
1990 [47]. Experimental studies investigating complement
inhibition in a clinically relevant context are rare, i.e. the
inhibitor was given after onset of ischemia, but confirmed
the protective potential of C5 inhibition [44]. Pigs are
highly recognized for the translational value of results
obtained [20], however C5 inhibition has not been tested as
no inhibitors for pig C5 have been available. Inhibition of
various other parts of the complement cascade by inhibi-
tion of complement factor 1 [21], treatment with soluble
complement receptor 1 [2], protecting the endothelium
with dextran sulfate [3] and tyrosine-O-sulfate [4] clearly
showed the potential of complement inhibition in pigs.
Clinical studies with the C5-antibody pexelizumab were
therefore performed without prior preclinical testing and
the results were disappointing [15, 31]. Administration of
the anti-C5 antibody during percutaneous coronary inter-
vention neither reduced myocardial infarction nor
decreased mortality [23]. However, a major concern with
these studies was that complement activation measured by
soluble C5b-9 (sC5b-9), the final activation product that
should be completely blocked by the antibody, increased
similarly in the treatment and the placebo groups [31]
leading to discussion whether a too low dose of the anti-C5
drug had been used.
The tick derived, specific C5 inhibitor coversin (Or-
nithodoros moubata Complement Inhibitor, OmCI), pre-
vents equally efficiently the cleavage of C5 in humans and
pigs [6, 32]. The potency of coversin in inhibiting C5 in
comparison to the clinically used C5 inhibitor eculizumab,
which has been derived from the same clone as its prede-
cessor pexelizumab [43], is not known. Additionally,
coversin also has an internal binding pocket for leukotriene
B4 (LTB4) [39], an arachidonic acid metabolite thought to
play a role in myocardial IRI [25]. However, the magnitude
and effect of LTB4 binding on the physiologic effects of
coversin are uncertain.
We hypothesized that the C5 inhibitor coversin could
reduce infarct size and improve myocardial function in a
clinically relevant porcine model of acute myocardial
infarction.
Materials and methods
Animal preparation
The ethics committee of the Norwegian Food Safety
Authority approved this study in pigs (approval number:
68/11-3811) and all experiments were performed in con-
cordance with the guidelines from Directive 2010/63/EU of
the European Parliament on the protection of animals used
for scientific purposes. Housekeeping, anesthesia, eutha-
nasia, and recording of hemodynamic and respiratory
parameters were performed in accordance to ARRIVE
guidelines as shown in table (Online Resource 1) and as
reported previously [5]. Briefly, anesthesia was induced in
twenty-one 20 kg pigs by intramuscular ketamine
(800 mg), azaperone (80 mg), atropine (1 mg) followed by
intravenous (iv) pentobarbital 1–3 mg kg-1 and main-
tained using iv morphine 1–2 mg kg-1 h-1 and isoflurane
1.0–1.5% in oxygen/air mixture. After sternotomy, a
silastic occluding tape was placed around the left anterior
descending (LAD) coronary artery distal to the second
diagonal branch allowing reversible complete occlusion.
Microdialysis catheters (CMA 71, 100 kDa cut-off, 2 cm
membrane, 1 ll min-1 flow, M Dialysis, Solna, Sweden)
were placed in the LAD dependent area and in a control
region supported by the left circumflex artery (Cx).
Experimental protocol
Ischemia was induced for a total of 40 min by LAD
occlusion, except for sham animals. Twenty minutes prior
to reperfusion, sixteen animals were randomized to
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treatment with coversin or saline (NaCl 0.9%, placebo
group), n = 8 in each group. Coversin (Akari Therapeutics
Plc, London, UK) has a plasma half-life of about 30 h due
to stable binding to C5 [18] and was diluted in saline. It
was given as a 1 mg kg-1 bolus, and followed by a con-
tinuous infusion of 0.036 mg kg-1 h-1 [5]. The control
group and the three sham animals received the same
amount of saline without coversin. Fifteen minutes before
euthanasia, iv magnetic resonance imaging (MRI) contrast
agent gadoteric acid (0.4 mM kg-1, Dotarem, Guerbet,
Paris, France) was given [34]. Just before euthanasia, LAD
was re-occluded and iv Evans Blue (2% in 40 ml phos-
phate buffered saline, Sigma Aldrich, St. Louis, MO, USA)
was given to delineate the area at risk (AAR). Euthanasia
was carried out by iv injection of pentobarbital (500 mg),
morphine (30 mg), and potassium chloride (50 mmol).
After euthanasia, the heart was excised and rinsed in ice-
cold saline.
Arterial blood samples were obtained prior to surgery,
after stabilization prior to induction of ischemia, at the end
of 40 min of ischemia, and every hour throughout the
reperfusion period. Samples were taken for blood gas
analysis, serum, and EDTA-plasma preparation and were
immediately cooled and centrifuged prior to storage
at -80 C. Microdialysis samples and thermal dilution
cardiac output were obtained at the same time points. After
euthanization, tissue samples were taken from the center of
the Evans blue free area (AAR), at the border of the Evans
blue free area (border zone) and in the Evans blue stained
Cx region (control area) and snap-frozen in approximately
1 ml OCTTM (Sakura Finetek Europe, Zoeterwoude, the
Netherlands) prior storage at -80 C.
Infarct size assessed by magnetic resonance imaging
After tissue sampling, air-filled balloons were placed in the
left and right ventricle. MRI analysis was performed using
a 3 Tesla scanner (Philips, the Netherlands). T1-weighted
images (3D FFE, TR/TE = 5.4/2.3 ms, flip angle 35,
BW = 434 Hz, 125 slices and scan duration = 02:15) with
a measured isotropic resolution of 0.8 mm covering the
entire heart were acquired using a quadrature head coil.
Additionally, T1 measurement sequence was performed
(Look Locker sequence: T1w TFE with ‘‘shared’’ inversion
pulse, TR/TE = 2.3/4.3 ms, flip angle = 3, inversion
delay = 38.4 ms, phase interval = 65.5 ms,
BW = 853 Hz, SENSE factor 2, isotropic resolution of
1 mm), and T1 maps were reconstructed using NordicIce
(NordicNeuroLab, Bergen, Norway). The segmentation of
the infarcted volumes was done in OsiriX [37]. T1map was
used to discriminate infarcted areas with the 3D region-
growing tool (threshold of 400). The used threshold lead to
inclusion of pericardium and endocardium as well but as
the amount is comparable and small in all groups and
subjective manual processing would have been necessary,
we did not subtract it from the total infarcted volume.
Infarction size (ml) was determined in T1 weighted images
and compared to the total left ventricular volume.
Infarct size assessed by histological staining
After MRI, the left ventricle was cut in 5 mm thick slices.
The non-stained AAR was dissected and immersed in
tetrazolium chloride (TTC, 1% in phosphate buffered saline,
Sigma Aldrich, St. Louis, MO, USA) at 38C for 20 min.
Slices were placed in 4% formaldehyde solution (Histolab
Products AB, Gothenburg, Sweden) on ice for 30 min prior
to digital scanning. Infarct size was determined as percent-
age of AAR as described previously [20] using Photoshop
CS5 (Adobe Systems Software Ltd., Ireland).
Echocardiography
Systolic left ventricular function was assessed by
echocardiography from a four-chamber view prior to
ischemia and at the end of the reperfusion period (GE
Vivid 7, Horton, Norway). Peak systolic velocity and
systolic displacement of the mitral plane were obtained
from pulse Doppler echocardiography and averaged from
the septum and the lateral wall (Echopac PC Version 112,
GE Vingmed Ultrasound, Horten, Norway).
Immunofluorescence analysis
The snap-frozen tissues were cut into 5 lm thick sections,
air-dried for 60 min and fixed with cold acetone for
10 min. They were either processed immediately or stored
at -80 C until further analysis. Then, after hydration, the
sections were stained using a two-step indirect
immunofluorescence technique. For E-selectin, the fol-
lowing primary and secondary antibodies were used:
mouse anti-human E-selectin (Sigma, St. Louis, MO, USA)
and goat anti-mouse IgG-Alexa546 (Molecular probes,
Carlsbad, CA, USA). The antibodies used for Fibrinogen-
like protein 2 (FGL-2) were rabbit anti-FGL2 (Aviva
Systems Biology Corp, San Diego, CA, USA) and sheep
anti-rabbit IgG-Cy3 (Sigma, St. Louis, MO, USA). A
nuclear staining was performed using 40,6-diamidino-2-
phenylindole (DAPI; Sigma, St. Louis, MO, USA). A flu-
orescence microscope (DMI4000B; Leica, Wetzlar, Ger-
many) was used to analyze the slides and the quantification
of fluorescence intensity was performed using Image J
software, version 1.50 (https://rsb.info.nih.gov/ij/) on TIFF
images. All pictures were taken under the same conditions
to allow for correct quantifications and comparison of
fluorescence intensities.
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In vitro assessment of complement inhibitory effects
of coversin and eculizumab
Human and porcine whole blood samples anticoagulated
with lepirudin (Celgene, Marburg, Germany) were pre-in-
cubated with coversin or eculizumab (Alexion Pharma-
ceuticals, CT, USA) in a twofold serial dilution (final
concentrations of 1.6, 0.8, 0.4, 0.2 and 0.1 lM) or PBS for
the uninhibited control in sterile polypropylene tubes for
5 min at 37 C. Subsequently, blood specimens were
stimulated with zymosan at a final concentration of 50 lg/
ml, or PBS for the negative control. After 30 min, the
reaction was stopped by adding EDTA (final concentration
10 mM), samples centrifuged (3000g, 15 min, 4 C). The
resulting plasma was stored at -80 C before analysis of
C5b-9. Human and porcine serum samples were pre-incu-
bated with coversin or eculizumab in a twofold serial
dilution (final concentrations of 3.2, 1.6, 0.8, 0.4, 0.2 and
0.1 lM) or PBS for the uninhibited control in sterile
polypropylene tubes for 5 min (room temperature) before
analysis for functional complement activity.
Functional complement activity and C5b-9 (TCC)
Commercially available enzyme immune assay (Comple-
ment System Screen Wieslab; Euro Diagnostica, Malmo¨,
Sweden) and murine anti-human C5b-9 antibody (clone
aE11, Dako, Glostrup, Denmark) were used according to
manufacturer’s instructions to detect functional comple-
ment activity and sC5b-9 production in plasma, respec-
tively. Both methods detect the respective human and pig
epitopes [41]. In tissue, the membrane form of C5b-9 was
visualized in frozen sections from the AAR, border zone
and control area. Tissue samples were incubated for 30 min
at room temperature using the murine anti-human C5b-9
antibody (clone aE11, Dako, Glostrup, Denmark) diluted
1/25 in Dako antibody diluent (Dako K8006, Glostrup,
Denmark), washed in phosphate buffered saline and stained
by Ventana ultra View Universal DAB Detection Kit
(Ventana Medical Systems, Inc., Tucson, AZ) according to
the manufacturer’s instructions. A Nikon Eclipse E1000M
microscope was used and photos were obtained with
original 409 magnification.
Myocardial metabolism and inflammation
Microdialysis fluid from the AAR and control Cx region
and EDTA-plasma was assessed for inflammatory media-
tors interleukin (IL)-1b, IL-6, IL-8, IL-10, and TNF using a
porcine multiplex cytokine assay on a Bio-Plex 100 system
(Bio-Rad, Hercules, CA, USA) as previously described [9].
LTB4 from plasma and myocardial tissue was measured
using a competitive enzyme immunoassay according to the
manufacturer’s instructions (R&D systems, Minnesota,
MN, USA).
Markers of cardiac injury
Serum troponin-T levels were determined at the institu-
tional clinical laboratory (Modular E170, Roche Diagnos-
tics, Switzerland). Plasma heart fatty acid binding protein
H-FABP levels were measured by ELISA in accordance to
manufacture’s instruction (Hycult Biotech, Uden, The
Netherlands).
Statistics
Investigators were blinded to the treatment during the
experiments and all analyses.
Two animals died immediately after reperfusion due to
ventricular fibrillation (one coversin and one placebo
treated animal) and were excluded. Thus, functional com-
plement activity was analyzed in 16 animals subjected to
LAD occlusion and three sham-operated animals. Com-
plete inhibition of all three complement pathways by
coversin treatment was confirmed in all animals, except for
one, which was excluded after statistical confirmation of
outlier behavior (Grubbs’ test, p\ 0.05). Thus, 15 animals
(seven coversin and eight control animals) were used in all
further analyses if not stated otherwise.
Two animals (one coversin and one control animal) had
significantly smaller AAR determined by Evans Blue
staining due to anatomical variations of the LAD and were
therefore excluded from MRI analysis. Microdialysis
catheters ceased function before 120 min of reperfusion in
two coversin and one control animal and statistical com-
parison was therefore done with five and seven animals,
respectively.
If not stated otherwise, values are presented as
mean ± standard deviation (SD). Values obtained for
coversin treated and control animals were compared at
defined time points using Mann–Whitney U test. Two-way
ANOVA was used if more than two groups had to be
compared. Linear mixed effect model (intervention as fixed
effect and subject number as random effect) was used to
compare groups throughout the whole study period. Mul-
tiple comparisons were post hoc Bonferroni corrected. The
Pearson correlation coefficient was calculated to compare
infarct sizes determined by TTC and MRI. Statistical
analyses were performed using SPSS 22 (IBM, Armonk,
NY, USA) and GraphPad Prism 6 (GraphPad Software, La
Jolla, CA, USA).
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Results
Effect of coversin on myocardial infarction size
Evaluation by histological staining
Myocardial ischemia and reperfusion led to an average
infarct size of 49.4 ± 14.2% (mean ± SD, necrotic tissue
as % of the AAR) in the control group. Coversin treated
animals showed an infarct size of 30.1 ± 14.0% of the
AAR, representing a significant reduction of 39% as
compared to controls (p = 0.03, Fig. 1a, b). The AAR was
comparable between coversin treated and control animals
as determined by Evans Blue staining (21.2 ± 6.4 and
25.5 ± 5.5% of left ventricular volume, respectively;
p = 0.12, data not shown).
Evaluation by post mortem MRI
Infarcted volume in the left ventricle was decreased from
21.1 ± 2.4% in placebo treated animals to 17.2 ± 2.7% in
coversin treated animals as determined by MRI (19%
reduction, p = 0.02, Fig. 1c, d). Infarction determined by
TTC staining and magnetic resonance imaging were highly
correlated (R = 0.92, p\ 0.01, Online Resource 2).
Sham-operated animals, in which the LAD was not
ligated, did not reveal any signs of myocardial ischemia
nor infarction evaluated by histological staining and MRI.
Also in all other analysis reported in this study, sham
treated animals were consistently stable at baseline levels
throughout the study period and are therefore not reported
in further results.
Effect of coversin on myocardial function
Myocardial function was measured by tissue Doppler
echocardiography, whereas cardiac output and stroke vol-
ume were measured by thermal dilution at start and end of
the experiment (Fig. 2). Peak systolic velocity was 29%
higher in the coversin treated animals than in the controls
(4.6 ± 1.1 and 3.3 ± 0.7 cm s-1, respectively; p = 0.01,
Fig. 2a). Likewise, systolic displacement was 31% higher
in coversin treated animals than in controls (7.4 ± 1.3 and
5.1 ± 0.7 mm, respectively; p\ 0.01, Fig. 2b). Stroke
volume was 16% higher in the coversin treated animals
than in the controls (23.4 ± 3.4 and 19.5 ± 2.4 ml,
respectively; p = 0.01, Fig. 2c). Cardiac output showed a
non-significant trend to higher values in coversin treated
animals compared to the controls (2.7 ± 0.4 and
2.3 ± 0.2 l/min, respectively; p = 0.09, Fig. 2d).
Fig. 1 Coversin reduced
infarction size. a Coversin (C5
inhibitor) reduced infarction in
the area at risk (AAR) by 39%,
p = 0.03 determined by TTC
staining. b TTC staining of the
AAR (example slices from one
animal in each group) shows
infarcted areas in white and
non-infarcted areas in red.
c Coversin reduced infarction in
the left ventricle by 19%,
p = 0.02 determined by
gadolinium stained magnetic
resonance imaging (MRI).
d Transversal (first row) and
frontal (second row) T1-
weighted MRI images of the
same animals shown in panel B
with shaded right ventricle as
only the left ventricle was
analyzed. White area and black
area within white area depict
infarction and non-perfused
infarction, respectively.
Horizontal line denotes mean
[n = 8 (placebo) and n = 7
(coversin)]. Mann–Whitney
U test. LV left ventricle
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Effect of coversin on local myocardial inflammation
Microdialysis
The inflammasome-related IL-1b was increased at the end
of reperfusion in the AAR only and this increase was
significantly blunted by coversin treatment (Fig. 3). IL-6
and IL-8 increased during reperfusion, both without sig-
nificant effect of coversin treatment, while IL-10 and TNF
did not increase form baseline levels (data not shown).
Immunofluorescence
In control animals, myocardial ischemia and reperfusion
led to increased expression of E-selectin in the border zone
of the AAR, while E-selectin in both the infarcted center of
the AAR and Cx control region was not changed (Fig. 4,
left panels). Coversin significantly reduced the E-Selectin
expression in the border zone (Fig. 4, middle and right
panels). FGL-2 was increased in the infarcted center of the
AAR and the Cx control region in comparison to sham
treated animals without a significant effect of coversin
(data not shown).
Systemic and local myocardial effect of coversin
on complement and LTB4
Complement activity was measured at all time points
throughout the experiment. Coversin completely ablated
complement activity measured via all the three comple-
ment activation pathways throughout the reperfusion per-
iod, whereas the activity remained unchanged in the
placebo group (Fig. 5a–c). Coversin treatment significantly
reduced sC5b-9 to levels below baseline, in contrast to the
placebo group and consistent with complete inhibition of
terminal complement (p\ 0.01, Fig. 5d). Dense deposition
of the C5b-9 complex in placebo treated animals was
observed in the AAR, in the border zone, and to a lesser
extent in the non-ischemic control region (Fig. 5e, left
panels). Coversin treatment almost completely prevented
C5b-9 deposition in AAR, the border zone, and non-is-
chemic control region (Fig. 5e, right panels).
Plasma LTB4 concentrations during reperfusion were
lower in coversin treated animals but not significantly
different from placebo (p = 0.07, Fig. 6a). Myocardial
LTB4 concentration was not affected by treatment in AAR,
border zone, nor non-ischemic control region (Fig. 6b).
Fig. 2 Coversin improved myocardial function. Tissue Doppler
echocardiography was evaluated from the mitral plane and averaged
from septal and lateral wall movements. Open bars represent control
and filled bars coversin treated animals. Systolic velocity was reduced
at 4 h after reperfusion in both groups but was 29%, p = 0.01 higher
in coversin compared to control animals (a). Likewise, systolic
displacement was 31%, p\ 0.01 higher in coversin treated animals in
comparison to placebo treated animals (b). Thermal dilution derived
stroke volume (c) was 14%, p = 0.01 higher, while cardiac output
(d) showed a trend of 16%, p = 0.09 increase in coversin treated
animals. Values presented as mean ± SD [n = 8 (placebo) and n = 7
(coversin)]. Mann–Whitney U test
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Fig. 3 Coversin reduced local
myocardial IL-1b production.
IL-1b obtained by microdialysis
was induced in the area at risk
(AAR) and not the control
region after 4 h of reperfusion.
Coversin treatment (filled bars)
significantly reduced IL-1b in
the AAR by 80% in comparison
to placebo treated animals (open
bars). Values presented as
mean ± SEM [n = 7 (placebo)
and n = 5 (coversin)]. Two-
way ANOVA with post hoc
Bonferroni correction for
multiple testing
Fig. 4 Coversin reduced E-selectin expression. Myocardium was
stained with antibody against E-selectin. E-selectin expression was
increased in placebo treated animals in the border zone of the AAR
and unchanged in the center of the AAR and non-ischemic Cx control
region (left panels). Coversin treatment led to significant decrease of
E-selectin, expressed by reduced density of staining (middle and right
panels). Horizontal line denotes mean [n = 8 (placebo) and n = 7
(coversin)]. Mann–Whitney U test
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Systemic effect of coversin as assessed by plasma
analyses
Plasma troponin T and H-FABP increased in both the
placebo and coversin groups during the reperfusion period
confirming myocardial cell damage during the ischemic
event (Fig. 7). Lower troponin T and H-FABP values were
obtained in coversin treated animals in comparison to
control animals throughout the reperfusion period without
reaching significance, though a trend for lower values was
observed for H-FABP (p = 0.07, Fig. 6b).
Plasma concentrations of IL-1b, IL-6, IL-8, IL-10 and
TNF remained at baseline levels throughout the study
period (data not shown).
Fig. 5 Coversin eliminated complement activity. Complement activ-
ity was assessed in plasma and the classical (a), lectin (b) and
alternative pathway (c) were monitored using C5b-9 deposition as
common readout. Coversin bolus treatment during coronary ischemia
led to significantly reduced complement activity in all pathways
(filled circles) and was not affected in control animals (open boxes).
Complement activity remained low in all three pathways throughout
the reperfusion period until the end of the experiment. Consequently,
the plasma soluble complement activation product sC5b-9 was
significantly reduced in plasma of coversin treated animals in
comparison to controls (d). Myocardium was stained with an
antibody against C5b-9 (e). Visually, deposition of C5b-9 (brown)
was markedly decreased in the area at risk, the border zone and the
non-ischemic control region in coversin treated animals in compar-
ison to placebo treated animals. a–d Values presented as mean ± SD
[n = 8 (placebo) and n = 7 (coversin)]. Linear mixed effect model.
CAU complement arbitrary units. e Results of two representative
animals are shown
20 Page 8 of 14 Basic Res Cardiol (2017) 112:20
123
Comparison of coversin and eculizumab
on complement activation
Coversin, but not eculizumab, effectively inhibited func-
tional complement activity in porcine serum (Fig. 8a–c),
while both were equally effective in human serum
(Fig. 8e–g). Similarly, formation of the fluid phase sC5b-9
by the complement activator zymosan in porcine whole
blood was efficiently inhibited by coversin, but not eculi-
zumab (Fig. 8d). Both inhibitors were again equally
effective in human whole blood where they completely
prevented zymosan-induced sC5b-9 formation (Fig. 8h).
Discussion
In this porcine study of myocardial IRI, C5 inhibition by
coversin prior and during reperfusion significantly reduced
infarct size and improved ventricular function. Complete
blockade of terminal complement pathway by coversin was
revealed by lack of systemic complement activity in
plasma and abolished deposition of C5b-9, which was
extensive in the AAR in the control group. Finally, IL-1b
and E-Selectin expression in the AAR were significantly
reduced by coversin.
Targeting the complement system at the terminal stage
preventing C5 cleavage is a reasonable approach as prox-
imal complement activity is left unaffected and thus
important immunoprotective and immunoregulatory func-
tions exerted particularly by C3 are preserved [12]. End
products of complement activation are C5a and C5b-9.
Membrane bound C5b-9 induces inflammatory responses
in the course of IRI by platelet and endothelial cell acti-
vation accompanied by leukocyte infiltration [11]. The
potent anaphylatoxin C5a is regarded as a crucial factor in
myocardial IRI [4, 24]. In our study, the detrimental effects
of C5 cleavage were prevented resulting in protective
effect on both infarct size and myocardial function. It is
noteworthy that comparable porcine studies where C5a
effect was diminished by C5a receptor antagonism [45] or
a C5a monoclonal antibody [1] showed less protection of
the AAR and no effect on ventricular function. This
highlights the importance of C5b-9 in myocardial reper-
fusion injury, while improvement of ventricular function
confirms the physiological relevance of our findings.
However, specific effects of coversin on myocardial func-
tion need to be investigated in studies observing long-term
effects after myocardial IRI.
Leukotrienes are important multifunctional mediators of
inflammation and promote neutrophil chemotaxis and
adherence to capillary walls [48]. LTB4 is expressed on
leucocytes after myocardial IRI [36], gets elevated in
plasma in the course of myocardial infarction [42] and has
been shown to be able to discriminate between cardiac and
non-cardiac chest pain [26]. Coversin has an internal
binding pocket capturing LTB4 and C5-inhibition prevents
LTB4 formation [5]. In the present study, LTB4 in plasma
did not significantly increase in the course of ischemia nor
during reperfusion in placebo treated animals. This may be
related to the short reperfusion time of 4 h in this study, as
a doubling of LTB4 in humans appears during the first 24 h
after acute myocardial infarction, probably in the course of
endothelial cell activation [42]. However, neither plasma
nor myocardial LTB4 concentrations were affected by
coversin treatment indicating a negligible effect of coversin
on LTB4 in this model. Furthermore, selective LTB4
blockade has only exhibited minor effects on myocardial
IRI in rodents [8]. These findings indicate that the main
Fig. 6 Coversin did not reduce LTB4. a LTB4 was assessed in
plasma throughout the study period. LTB4 showed a non-significant
trend to lower values during reperfusion in coversin treated animals
compared to placebo. LTB4 in myocardial tissue from three different
regions at the end of the experiment was not affected by Coversin
treatment (filled bars) in comparison to control (open bars) (all
p[ 0.1). Values presented as mean ± SD. a Linear mixed effect
model, b two-way ANOVA with post hoc Bonferroni correction for
multiple testing
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coversin related effects observed in this study could be
attributed to C5 inhibition, while LTB4 inhibition might
add to the effect of C5 inhibition in long-term studies.
Large clinical studies have explored the efficacy of C5
inhibition using pexelizumab, a monoclonal antibody
blocking C5 cleavage, on the outcome of myocardial
infarction treated with thrombolysis [30] and percutaneous
coronary intervention [15, 23]. These studies did not
demonstrate convincing beneficial effects and several
questions have arisen in the aftermath. Firstly, the dosing
regimen of pexelizumab was only tested once, yet this has
been decisive for dosages in subsequent studies [15].
Secondly, complement activity was insufficiently inhibited
in both studies, and blood samples from the last trial
revealed a similar increase in the formation of sC5b-9 in
both placebo and treatment group [31]. This supports the
notion that full inhibition of C5 is necessary to effectively
reduce the harmful effects of complement activity in the
heart. Ideally, coversin should have been compared to the
formerly used pexelizumab or today’s clinically used
eculizumab, which all inhibit cleavage of C5 at different
binding sites [27]. However, pexelizumab and eculizumab
are monoclonal antibodies with specificity for human C5
only [10] and we have shown that they do not interact with
porcine C5. In this study, 0.85 lM coversin was used. In
the clinical trials, 1.2 lM pexelizumab was used [14],
which is equivalent to 0.6 lM eculizumab because of the
double-binding property of the antibody eculizumab in
contrast to the single-chain variant pexelizumab [38]. Thus,
slightly higher doses of inhibitors were used in this study
compared to the clinical studies, which may explain the
successful prevention of reperfusion injury in this study but
more importantly add evidence to the assumption that the
pexelizumab dose may have been too low in order to
achieve full C5 inhibition. Thirdly, administration of the
C5 inhibitor in the clinical studies was probably given too
late, only minutes prior to reperfusion in the hospital [23].
Therapy aiming at reduction of myocardial reperfusion
injury should be initiated as early as possible after diag-
nosis of ischemia [22]. In this study, we aimed to mimic the
clinical situation and initiated coversin treatment with a
considerable time-gap prior to reperfusion. This is com-
parable to the clinical situation when medical treatment is
started at the time of diagnosis in the prehospital setting
with a time-gap prior to interventional reperfusion therapy.
This approach should be easily transferrable to clinical
trials.
Coversin treatment abolished IL-1b induction, which is
cleaved in the inflammasome from inactive proIL-1b and is
regarded as an inducer of sterile inflammation in myocar-
dial IRI [46]. Interestingly, C5 activation and membrane
bound C5b-9 have been shown to directly activate the
inflammasome [29, 33], suggesting that reduced cell death
and significant reduction of IL-1b observed in the present
study is related to C5-inhibition. E-Selectin is essential for
leukocyte recruitment, is a good marker of endothelial cell
activation and the expression is IL-1b dependent [33].
Thus, the observed reduction in E-selectin expression in the
border zone of the AAR in the present study might be
caused by C5 inhibition through IL-1b, explaining the
reduced reperfusion injury. The lack of significant increase
in the rest of the cytokines might be explained by the short
reperfusion time, as generation of cytokines is time-de-
pendent and additionally affected by the limited recovery
in microdialysis [28].
Pigs do not possess coronary collaterals, while humans
experiencing myocardial ischemia often do. To compensate
for this limitation, we therefore adopted the length of the
occlusion period in this study (40 min) to a comparable
length of 4 h of infarction in man [17]. Isoflurane was used
Fig. 7 Coversin did not significantly decrease plasma markers of
myocardial ischemia. Troponin T (a) and H-FABP (b) were detected
in plasma throughout the study period. Myocardial ischemia lead to
an increase in troponin T and H-FABP in both control (open boxes)
and coversin treated (filled circles). Coversin treated animals showed
a trend towards lower H-FABP levels throughout the whole reper-
fusion period without reaching significance in comparison to control
animals (troponin T: p = 0.39; H-FABP: p = 0.07). Values presented
as mean ± SEM [n = 8 (placebo) and n = 7 (coversin)]. Linear
mixed effect model
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Fig. 8 Coversin, but not eculizumab, inhibits porcine complement
activation. Complement inhibitory effect of coversin (filled circles)
and eculizumab (open circles) were assessed in the functional
classical (a, e), lectin (b, f), and alternative pathway (c, g) assays in
porcine (a–c) and human (e–g) serum using percentage of solid phase
C5b-9 deposition as readout. Porcine (d) and human (h) whole blood
was incubated with the complement activator zymosan and the effect
of the inhibitors was examined using the soluble sC5b-9 complex as
readout. Coversin, but not eculizumab, effectively inhibited porcine
complement activity in a dose dependent manner, and was effective at
the calculated in vivo concentration of 0.8 lM used in this study.
Human complement activity was effectively inhibited by both
inhibitors in a dose dependent manner. Complement activity of all
three pathways was analyzed in duplicates and plasma from zymosan
activated whole blood samples was analyzed in triplicates. CAU
complement arbitrary units, neg ctr negative control, sC5b-9 soluble
C5b-9
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as anesthetic agent in this study, although the cardiopro-
tective properties of isoflurane are known. We chose this
gas as it confers myocardial stability. Both groups received
identical amounts of isoflurane and the infarction size in
the positive control group was considerable and compara-
ble to similar studies in pigs [7]. Thus, the results obtained
by coversin treatment appear coversin and not isoflurane
mediated. Duration of treatment was relatively short with
4 h of reperfusion and conclusions about long-term
myocardial complement activation, function and effect of
coversin on LTB4 can therefore not be made. Thus, a pig
closed-chest study with longer periods of treatment,
reperfusion and observation should be performed prior to
clinical trials investigating coversin in myocardial IRI
[13, 40]. The trend to lower troponin-T and H-FABP levels
during reperfusion in combination with reduced infarct size
in coversin treated animals indicate that indeed myocardial
IRI was reduced by coversin.
Pigs are regarded as one of the most translatable animal
models in myocardial IRI research. Additionally, coversin
has the same C5 binding characteristics in humans and pigs
and coversin is already in clinical use in one eculizumab
resistant patient as well as in phase Ib and II clinical trials
(Clinicaltrials.gov NCT02591862 as well as producer’s
webpage akaritx.com). Thus, the approach outlined in this
study including the dosing regimen might be directly
transferable to a clinical study investigating myocardial IRI
when the long-term effects of coversin on myocardial cell
survival and function as discussed above have been eluci-
dated, complying with the proposed outline of future
clinical studies targeting reperfusion injury in patients with
myocardial infarction [16, 19].
In conclusion, we show in this clinically relevant model
of myocardial IRI that complement inhibition of C5 redu-
ces infarction size, possibly through reduction of IL-1b and
E-selectin, and improves ventricular function. Accordingly,
on the basis of concerns with previous studies and the
results of this study we reason that there is a need to
reconsider the use of complement inhibition especially at
the level of C5 in clinical myocardial infarction.
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